As gain multiple approvals for their blockbuster weight loss drugs, a new model for developing drugs for metabolic disorders may be emerging in the pharmaceutical sector.
In July, the European Medicines Agency鈥檚 (EMA) Committee for Medicinal Human Products (CHMP) recommended a label expansion for Novo Nordisk鈥檚 semaglutide to include its use as a drug for reducing cardiovascular risk. Apart from its popular use as a and type 2 diabetes, the drug, which is marketed as Ozempic and Wegovy, is also being developed for several different metabolic disorders including metabolic dysfunction-associated steatohepatitis (MASH), peripheral arterial disease, kidney disease, and more.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAccording to GlobalData, there are currently 202 ongoing clinical trials investigating semaglutide for its different uses.
GlobalData is the parent company of Pharmaceutical Technology.
Similarly, the FDA first approved Eli Lilly鈥檚 weight loss and diabetes drug tirzepatide in May 2022 for the treatment of type 2 diabetes, which helped the pharmaceutical giant earn $9.35 billion in overall 2023 revenues. Now, Eli Lilly is also investigating tirzepatide, which is marketed as Mounjaro and Zepbound, for multiple indications including MASH, obstructive sleep apnoea, and more.
Both Eli Lilly and Novo Nordisk鈥檚 therapies are glucagon-like peptide-1 receptor agonists (GLP-1RAs), which have risen in prominence over the last few years. This class of drugs shows major potential for several metabolic disease areas, says Dr. Paul Brennan, a clinical lecturer at the University of Dundee, Scotland. The success of the GLP-1 receptor agonists has opened a wider discussion about the possibilities of therapeutic development for several metabolic disorders, says Brennan.
In addition to the pharmaceutical giants鈥� plans for their approved drugs, other pharmaceutical companies are also choosing to expand their strategic plans from the outset, funneling money towards several different metabolic conditions from the beginning of the drug development cycle. , , and smaller biotechs like are a few of the companies developing therapies for sleep apnoea, heart failure with preserved ejection fraction, and more indications.
鈥淲e do not always know the downstream effects of any new agent until we have it in the clinic and watch people,鈥� says Dr. Margaret Morris, the head of pharmacology at the University of New South Wales鈥檚 School of Medical Sciences, Sydney. As such, the possible uses of several pipeline weight loss drugs could extend much further than initially expected, she says.
The metabolic drug label
鈥淭here are people who are obese, [but] who do not have type 1 or type 2 diabetes鈥hey have what's called metabolic syndrome,鈥� says Dr. Morley Hollenberg, a professor in the Department of Physiology and Pharmacology at the University of Calgary, Calgary, Canada.
The US National Institutes of Health (NIH) describes metabolic syndrome as a 鈥済roup of conditions that together raise your risk of coronary heart disease, diabetes, stroke, and other serious health problems. Metabolic syndrome is also called insulin resistance syndrome.鈥� Markers of this include low high-density lipid (HDL) cholesterol, high triglycerides, high blood glucose levels, and more. Thus, metabolic syndrome encompasses symptoms and risk factors that can lead to several metabolic conditions.
It may not be 鈥渙utlandish鈥� to see a regulatory label for drugs to treat metabolic disorders overall in the future, says Hollenberg.
Several investigational metabolic disorder therapies act to reduce factors such as oxidative stress, steatosis, and fibrosis, which are common symptoms or risk factors for several diseases such as heart failure, says Brennan. For example, 鈥� recently FDA-approved therapy, Rezdiffra (resmetirom) for non-alcoholic steatohepatitis, which is now called MASH, has been shown to have an unintended benefit of reducing low-density lipoprotein (LDL) levels and cardiovascular disease. 鈥淸Among patients with] metabolic dysfunction-associated liver disease, 5% of patients will get end-stage liver disease, and the other 90鈥�95% will develop cardiovascular disease and cancer, including hepatocellular carcinoma,鈥� he adds. Thus, regulators already view these disorders and their impacts in tandem with each other, says Brennan.
Currently, there is a push for clinicians to look at metabolic markers initially if patients experience any metabolic syndrome symptoms, says Hollenberg. Sometimes, this also translates to clinical trials, he says.
If an agent is effective in one metabolic disorder, it is likely that it will be 鈥渧ery useful鈥� in other metabolic conditions, says Hollenberg.
Hollenberg鈥檚 lab is currently investigating the type 2 diabetes drug metformin鈥檚 general use for metabolic syndrome. Metformin is an adenosine monophosphate (AMP) protein kinase inhibitor that is commonly prescribed in type 2 diabetes and acts by modulating glucose pathways. 鈥淢etformin protects the endothelium from high glucose damage, even without affecting the blood glucose levels,鈥� explains Hollenberg. He says that this can reduce vascular diseases such as peripheral vascular disease, carotid artery disease, and pulmonary embolisms.
Designing drug development for metabolic disorders
Some companies are extending the remit of what biomarkers in earlier trials are expected to show so they can identify other potential metabolic disorders for a drug鈥檚 label.
The triglyceride, beta cell function, and blood pressure-related endpoints measured in Amgen鈥檚 Phase II MASH trial (NCT05669599) for MariTide (maridebart cafriglutide) could give the company an idea of the drug鈥檚 future potential for other metabolic conditions, explains Dr. Dimitris Papamargaritis, a National Institute for Health and Care Research (NIHR) clinical lecturer in diabetes and endocrinology at the University of Leicester, UK. MariTide is a gastric inhibitory polypeptide receptor (GIPR)/glucagon-like peptide-1 receptor (GLP-1R) bispecific molecule in development for the treatment of weight loss, type 2 diabetes, and MASH.
GLP-1 receptor agonists are not the only drugs being investigated in this manner. Dr. Fiona Murray, a senior lecturer at the University of Aberdeen, is currently investigating the potential of a target, GPR75, for therapeutic development for metabolic syndrome. 鈥淕PR75 seems to encompass a lot of the health problems that people are at risk of in metabolic disease. This includes things like heart disease, high blood pressure, NASH, and diabetes,鈥� says Murray.
Murray鈥檚 lab discovered the target while observing that patients with pulmonary arterial hypertension had an increased expression of GPR75. Murray and her colleagues are investigating an endogenous ligand for the receptor such that the target could be modulated using antibody therapies, clustered regularly interspaced short palindromic repeats (CRISPR), or an antagonist. 鈥淲e鈥檝e already had a lot of interest from industry,鈥� says Murray, adding that the lab is partnering with a few undisclosed biotechs.
Once a potential GPR75-targeting drug is in human trials, Murray predicts a global approach where it is investigated for several metabolic disorder-related diseases. She says that the attention surrounding metabolic diseases as a whole has jumped significantly during her time working in the space, going past larger disease sections like diabetes and hypertension, and getting closer to how 鈥淚f you鈥檙e able to limit the progression of metabolic disease, you鈥檒l probably be able to blunt the progression of other diseases,鈥� she adds.
According to Murray, public funding from places like The British Heart Foundation and the UK Research and Innovations鈥� Medical Research Council has also increased due to the 鈥渄rive to deal with the umbrella of metabolic diseases going forward鈥�.
鈥淔inding a target that is able to tap into all of these risk factors at the same time would be something really exciting, 鈥� adds Brennan. US regulators have also stepped up their metabolic disease focus, with the FDA launching the Committee for the Evaluation of Genetic Metabolic Disease Treatments in December 2023, while the National Cancer Institute is offering funding opportunities for obesity policy evaluation ahead of January 2025.
